121 related articles for article (PubMed ID: 38479044)
1. Olfactory threshold as a biomarker of long-term relapse activity in multiple sclerosis.
Berek K; Hegen H; Auer M; Barket R; Di Pauli F; Hocher J; Krajnc N; Zinganell A; Deisenhammer F; Berger T; Bsteh G
Mult Scler Relat Disord; 2024 May; 85():105545. PubMed ID: 38479044
[TBL] [Abstract][Full Text] [Related]
2. Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis.
Berek K; Hegen H; Auer M; Barket R; Di Pauli F; Hocher J; Krajnc N; Zinganell A; Deisenhammer F; Berger T; Bsteh G
Mult Scler; 2024 Jan; 30(1):55-62. PubMed ID: 37850472
[TBL] [Abstract][Full Text] [Related]
3. Olfactory threshold predicts treatment response in relapsing multiple sclerosis.
Bsteh G; Hegen H; Berek K; Altmann P; Auer M; Di Pauli F; Haider L; Leutmezer F; Rommer P; Walchhofer LM; Wurth S; Zinganell A; Deisenhammer F; Berger T
Mult Scler; 2022 Sep; 28(10):1541-1552. PubMed ID: 35282741
[TBL] [Abstract][Full Text] [Related]
4. Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
Bsteh G; Berek K; Hegen H; Teuchner B; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2020 Jan; 26(1):57-68. PubMed ID: 30465490
[TBL] [Abstract][Full Text] [Related]
5. Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
Bsteh G; Hegen H; Ladstätter F; Berek K; Amprosi M; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Reindl M; Berger T; Lutterotti A
Mult Scler; 2019 Feb; 25(2):267-274. PubMed ID: 29185867
[TBL] [Abstract][Full Text] [Related]
6. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
7. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
8. Transient impairment of olfactory threshold in acute multiple sclerosis relapse.
Bsteh G; Hegen H; Ladstätter F; Berek K; Amprosi M; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Lutterotti A; Berger T
Mult Scler Relat Disord; 2018 Jul; 23():74-77. PubMed ID: 29783156
[TBL] [Abstract][Full Text] [Related]
9. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.
Yaldizli Ö; Penner IK; Yonekawa T; Naegelin Y; Kuhle J; Pardini M; Chard DT; Stippich C; Kira JI; Bendfeldt K; Amann M; Radue EW; Kappos L; Sprenger T
Eur J Neurol; 2016 Mar; 23(3):510-9. PubMed ID: 26699999
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
11. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
12. Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study.
Kania K; Pawlak MA; Forycka M; Wiłkość-Dębczyńska M; Michalak S; Łukaszewska A; Wyciszkiewicz A; Wypych A; Serafin Z; Marcinkowska J; Kozubski W; Kalinowska-Łyszczarz A
Neurol Neurochir Pol; 2024; 58(2):176-184. PubMed ID: 38324117
[TBL] [Abstract][Full Text] [Related]
13. Multiple Sclerosis Progression and Relapse Activity in Children.
Iaffaldano P; Portaccio E; Lucisano G; Simone M; Manni A; Guerra T; Paolicelli D; Betti M; De Meo E; Pastò L; Razzolini L; Rocca MA; Ferrè L; Brescia Morra V; Patti F; Zaffaroni M; Gasperini C; De Luca G; Ferraro D; Granella F; Pozzilli C; Romano S; Gallo P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Banfi P; Lugaresi A; Totaro R; Spitaleri D; Cocco E; Di Palma F; Maimone D; Valentino P; Torri Clerici V; Protti A; Maniscalco GT; Salemi G; Pesci I; Aguglia U; Lepore V; Filippi M; Trojano M; Amato MP;
JAMA Neurol; 2024 Jan; 81(1):50-58. PubMed ID: 38010712
[TBL] [Abstract][Full Text] [Related]
14. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
Chen B; Ji SQ; Shen F; Tian DS; Bu BT
Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
[TBL] [Abstract][Full Text] [Related]
15. Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis.
Carotenuto A; Moccia M; Costabile T; Signoriello E; Paolicelli D; Simone M; Lus G; Brescia Morra V; Lanzillo R;
Sci Rep; 2019 Dec; 9(1):18074. PubMed ID: 31792347
[TBL] [Abstract][Full Text] [Related]
16. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
18. Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Wnuk M; Drabik L; Marona M; Szaleniec J; Bryll A; Karcz P; Kolasinska J; Kolasinska M; Ziekiewicz M; Skladzien J; Popiela T; Slowik A
Ear Nose Throat J; 2022 Dec; 101(10):640-644. PubMed ID: 33236917
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
20. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
Bsteh G; Hegen H; Teuchner B; Amprosi M; Berek K; Ladstätter F; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2019 Feb; 25(2):196-203. PubMed ID: 29095097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
